Time to Move the Goalposts? Examining Strategies to Advance HBV Management

Nov 11 2023
Room 311 - Hynes Convention Center
12:30 - 2:00 PM EST

Description

Supported by: GlaxoSmithKline

Organized by: Clinical Care Options

Presenters:

Ira M. Jacobson, MD

Tatyana Kushner, MD, MSCE

Paul Y. Kwo, MD

Join expert faculty as they provide education, perspectives, and recommendations for early HBV treatment and the evolving role of quantitative HBsAg monitoring in people living with chronic hepatitis B.

Learning Objectives:

  1. Select appropriate candidates for early HBV treatment after weighing drug-related considerations, cost-benefit considerations, and impact on patient outcomes
  2. Outline the role of quantitative HBsAg in monitoring patients with CHB, including evaluating disease status and predicting disease progression, treatment response, and functional cure
  3. Identify current and future clinical scenarios where quantitative HBsAg monitoring is beneficial to patient management

CME Hours: Maximum of 1.50 AMA PRA Category 1 Credits™

For more information and to register, visit: https://www.clinicaloptions.com/2023AASLD